Top Suppliers:I want be here


29331-92-8

29331-92-8 structure
29331-92-8 structure

Name Licarbazepine
Synonyms 5-hydroxy-5,6-dihydrobenzo[b]benzazine-11-cboxamide
10-Hydroxy-10,11-dihydrocbamazine 1.0 mg/ml in Acetonitrile
GP 47779-d3
10,11-Dihydro-10-hydroxy-5H-dibenz(Z)[b,f]azin-5-cboxamide
10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azine-5-cboxamide
Licarbazepine,10,11-Dihydro-10-hydroxy-5H-dibenz(Z)[b,f]azepin-5-carboxamide
10-hydroxy-10,11-dihydro-5H-dibenzo[b,f]azine-5-cboxaMide
10-Hydroxy-10,11-dihydrocbamezine-d3
Licbazine
10,11-hydroxy-10,11 Dihydrocbamezer
10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide,Licarbazepine
icbazine
10,11-Dihydro-10-hydroxycbamazine in methanol
10-Hydroxy-10,11-dihydrocbamazi
10,11-Dihydro-10-hydroxycbamazine 100 μg/mL in Acetonitrile
(±)-10-Hydroxy-10,11-dihydro-5H-dibenz[b,f]azine-5-cbox
Dihydrohydroxy cbamazine-D4
10,11-Dihydro-10-hydroxy-Cbamazin
10,11-Dihydro-10-Hydroxycbamazine solution
1H-Benzimidazole,2-(6-methoxyethyl)
Oxcbazine Hydroxy Impurity
LICBAZINE SEE
10,11-Dihydro-10-hydroxycarbamazepine
Licbazine (10,11-Dihydro-10-hydroxycbamazine), Active oxcbazine metabolite
(±)-10-Hydroxy-10,11-dihydro-5H-dibenz[b,f]azine-5-cboxaMide
BIA -d3
10,11-dihydro-10-Hydroxy CbamazineQ: What is 10,11-dihydro-10-Hydroxy Cbamazine Q: What is the CAS Number of 10,11-dihydro-10-Hydroxy Cbamazine Q: What is the storage condition of 10,11-dihydro-10-Hydroxy Cbamazine Q: What e the applications of 10,11-dihydro-10-Hydroxy Cbamazine
5H-Dibenz[b,f]azine-5-cboxaMide,10,11-dihydro-10-hydroxy
5-Cbamoyl-10,11-dihydro-5H-dibenzo[b,f]azine-10-ol
10,11-Dihydro-10-hydroxy cbamazine D7
10,11-Dihydro-10-hydroxy
10,11-Dihydro-10-hydroxy Carbamazepine
10-Hydroxy-10,11-dihydrocbamezine
Hydroxycbamazine
(±) -10,11-Dihydro-10-hydroxy-5H-dibenzo[b,f]azine-5-cboxamide
6-hydroxy-5,6-dihydrobenzo[b]benzazine-11-cboxamide
10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azine-5-cboxamide-d3
Licbazine Racemate
10,11-Dihydro-10-hydroxycbazine-d3
Description Licarbazepine (BIA 2-005; GP 47779) is a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects[1].
Related Catalog
Target

Sodium Channel[1]

In Vivo Eslicarbazepine acetate (ESL) is an oral pro-drug that is rapidly and extensively metabolized by the liver via a hydrolytic first-pass metabolism into S-Licarbazepine, the biologically active drug. The plasma level of the prodrug remains below quantification[1]. ESL is a potent antiepileptic agent with a spectrum of action essentially limited to partial-onset and generalized tonic-clonic seizures. Its main mechanism of action is by blocking the voltage-gated sodium channel. ESL works by blocking the voltage-gated sodium channel, which play an essential role in the generation and propagation of the epileptic discharge. ESL is well absorbed after oral administration with a bio-availability about 16% higher than that observed after an equivalent dose of Oxcarbazepine (OXC)[1].
References

[1]. Rajinder P Singh, et al. A review of eslicarbazepine acetate for the adjunctive treatment of partial-onset epilepsy. J Cent Nerv Syst Dis. 2011 Jul 20;3:179-87.

Density 1.336g/cm3
Boiling Point 431.3ºC at 760mmHg
Melting Point 186-189ºC
Molecular Formula C15H14N2O2
Molecular Weight 254.28400
Flash Point 214.6ºC
Exact Mass 254.10600
PSA 66.56000
LogP 3.25820
Vapour Pressure 3.33E-08mmHg at 25°C
Index of Refraction 1.677
Storage condition Store at RT
Symbol GHS02 GHS07
GHS02, GHS07
Signal Word Danger
Hazard Statements H225-H302 + H332-H319
Precautionary Statements P210-P305 + P351 + P338
Hazard Codes N,Xn,F
Risk Phrases 51/53-36-20/21/22-11
Safety Phrases 61-36/37-26-16
RIDADR UN 3077 9 / PGIII
HS Code 2933990090

~90%

29331-92-8 structure

29331-92-8

Literature: KANDULA, Mahesh Patent: WO2013/167985 A1, 2013 ; Location in patent: Paragraph 00102; 00103 ;

~91%

29331-92-8 structure

29331-92-8

Literature: Portela and Ca., S.A. Patent: EP1477480 A1, 2004 ; Location in patent: Page 6, 7 ;

~91%

29331-92-8 structure

29331-92-8

Literature: RANBAXY LABORATORIES LIMITED; HIRPARA, Ketan; KHANDURI, Chandra, Has; SHARMA, Mukesh, Kumar Patent: WO2013/8194 A2, 2013 ; Location in patent: Page/Page column 12; 13 ;

~68%

29331-92-8 structure

29331-92-8

Literature: Panunzio, Mauro; Campana, Eileen; Breviglieri, Gabriele Patent: US2008/221320 A1, 2008 ; Location in patent: Page/Page column 2 ;

~%

29331-92-8 structure

29331-92-8

Literature: Tian, Maoqun; Abdelrahman, Aliaa; Weinhausen, Stephanie; Hinz, Sonja; Weyer, Stefanie; Dosa, Stefan; El-Tayeb, Ali; Mueller, Christa E. Bioorganic and Medicinal Chemistry, 2014 , vol. 22, # 3 p. 1077 - 1088

~%

29331-92-8 structure

29331-92-8

Literature: Kittelman, Matthias; Lattmann, Rene; Ghisalba, Preste Bioscience, Biotechnology, and Biochemistry, 1993 , vol. 57, # 9 p. 1589 - 1590
HS Code 2933990090
Summary 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.